Cibinqo is owned by Pfizer.
Cibinqo contains Abrocitinib.
Cibinqo has a total of 3 drug patents out of which 0 drug patents have expired.
Cibinqo was authorised for market use on 14 January, 2022.
Cibinqo is available in tablet;oral dosage forms.
Cibinqo can be used as treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable.
Drug patent challenges can be filed against Cibinqo from 2026-01-14.
The generics of Cibinqo are possible to be released after 19 February, 2034.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(10 years from now) | |
US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 14, 2027 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: 2026-01-14
Market Authorisation Date: 14 January, 2022
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET;ORAL
4
United States
3
Lithuania
3
Hungary
2
Denmark
2
Slovenia
2
Croatia
2
Portugal
2
Cyprus
2
Spain
2
Poland
2
RS
2
China
2
Japan
2
ME
2
European Union
1
Israel
1
South Africa
1
IB
1
Turkey
1
Mexico
1
Australia
1
Hong Kong
1
Morocco
1
Philippines
1
Uruguay
1
Norway
1
Cuba
1
Costa Rica
1
Moldova, Republic of
1
Singapore
1
Argentina
1
Brazil
1
Malaysia
1
Netherlands
1
Peru
1
Korea, Republic of
1
Dominican Republic
1
Chile
1
Taiwan, Province of China
1
Georgia
1
Ukraine
1
EA
1
Canada
1
Tunisia
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic